603 results on '"Lee, John K."'
Search Results
2. A combinatorial genetic strategy for exploring complex genotype–phenotype associations in cancer
3. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation
4. Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth
5. Epileptogenesis in Common Parasitic Infections
6. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
7. Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis
8. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
9. Teaching and Learning Inquiry Framework
10. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
11. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
12. Amygdala subfield and prefrontal cortex abnormalities in patients with functional seizures
13. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression
14. Entropic analysis of antigen-specific CDR3 domains identifies essential binding motifs shared by CDR3s with different antigen specificities
15. Targeting RET Kinase in Neuroendocrine Prostate Cancer
16. Development of Cancer Immunotherapies
17. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
18. Genomic Characterization of Prostatic Basal Cell Carcinoma
19. MP35-18 AGREEMENT BETWEEN TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) AND RADICAL CYSTECTOMY (RC) PATHOLOGY IN PATIENTS WITH BLADDER CANCER SUBTYPE HISTOLOGY
20. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
21. Clinical MRI morphological analysis of functional seizures compared to seizure-naïve and psychiatric controls
22. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
23. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
24. Development of Cancer Immunotherapies
25. A minority of patients with functional seizures have abnormalities on neuroimaging
26. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program
27. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate
28. Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris
29. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer
30. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy
31. Precision Medicine-Enabled Cancer Immunotherapy
32. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
33. Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies*
34. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
35. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
36. Supplementary Figure 14 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
37. Supplementary Figure 8 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
38. Data from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
39. Supplementary Table 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
40. Supplementary Figure 5 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
41. Supplementary Figure 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
42. Supplementary Figure 6 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
43. Supplementary Table 1 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
44. Supplementary Figure 7 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
45. Supplementary Figure 9 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
46. Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers
47. Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer
48. De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc
49. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
50. A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.